ARCHIVES

CMS Considering Regulatory Standards for Drug Company Bundling of Products.

This article is from The Cancer Letter archive.

Vol. 32 No. 37 | October 20, 2006

Download PDF Visit The Full Archive

Related Articles

NCAB Delays Approval Of New Comprehensive Center Guidelines

October 12, 1979

Funding NCI Bypass Budget The “Very Least” Congress Could Do, Congressman Durbin Says

July 13, 1990

ACS Asks Higher NCI Authorization

March 24, 1978

Federal Coordinating Council On Comparative Effectiveness Research To Hold Meeting

April 10, 2009

FDA Approves Ixempra For Metastatic Breast Cancer Resistant To Other Therapy

October 26, 2007

Breast Cancer Progress Report Summaries

November 14, 1975